当前位置:上海富雨生物科技有限公司>>细胞库 / 细胞培养>>普通细胞>> SV40转化的非洲绿猴肾细胞C
SV40转化的非洲绿猴肾细胞COS-7
种属 | 猴 |
别称 | Cos-7; COS7; Cos7; CV-1 in Origin Simian-7 |
组织来源 | 肾脏 |
疾病 | 转化细胞系 |
传代比例/细胞消化 | 1:2传代 ,消化2-3分钟 |
培养基配置 | DMEM培养基;10%胎牛血清;1%双抗 |
简介 | COS-7细胞源自CV-1细胞 ,经带有编码野生型T抗原的起始失活突变的SV40转染得到 |
形态 | 成纤维细胞样 |
生长特征 | 贴壁生长 |
倍增时间 | ~35-48h |
基因表达 | T antigen |
培养条件 | 气相:空气 ,95% ;二氧化碳 ,5%。 温度:37摄氏度 ,培养箱湿度为70%-80%。 |
冻存条件 | 冻存液:90%FBS ,DMSO 10%, 或使用非程序冻存液:货号JY-H040 |
保藏机构 | ATCC; CRL-1651 |
产品使用 | 于科学研究 ,不可作为动物或人类疾病的治疗产品使用。 |
Results: The cohort had a mean age of 39 years and included patients with severe polytrauma. Technical success was achieved in 95% of cases, with no intraoperative deaths or need for open surgical conversion. Perioperative complications were minimal, and the reintervention rate was 5.3%. This study evaluates 10 years of clinical experience managing TAI with TEVAR. Long-term follow-up, with a median duration of 29 months, revealed no graft-related complications or secondary interventions. Imaging confirmed sustained graft integrity, and clinical outcomes were favorable.
Conclusion: TEVAR is a reliable and effective treatment for traumatic aortic injuries, offering excellent technical success rates and minimal perioperative and long-term complications. This study highlights TEVARs advantages in managing polytrauma patients and its role as a minimally invasive alternative to open surgery. Additionally, the findings emphasize the need for comprehensive long-term follow-up protocols. Future research should aim to address challenges related to device durability and the integration of advanced imaging techniques to further enhance patient outcomes and broaden the applicability of TEVAR in trauma care.
请输入账号
请输入密码
请输验证码
以上信息由企业自行提供,信息内容的真实性、准确性和合法性由相关企业负责,化工仪器网对此不承担任何保证责任。
温馨提示:为规避购买风险,建议您在购买产品前务必确认供应商资质及产品质量。